Sun Biomedical (ASX:SBN) Interest Expense : A$0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Sun Biomedical Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Sun Biomedical's interest expense for the six months ended in Dec. 2023 was A$ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was A$0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Sun Biomedical's Operating Income for the six months ended in Dec. 2023 was A$ -6.76 Mil. Sun Biomedical's Interest Expense for the six months ended in Dec. 2023 was A$ 0.00 Mil. Sun Biomedical has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Sun Biomedical Interest Expense Historical Data

The historical data trend for Sun Biomedical's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sun Biomedical Interest Expense Chart

Sun Biomedical Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Interest Expense

Get a 7-Day Free Trial

Sun Biomedical Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

Sun Biomedical Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

Sun Biomedical (ASX:SBN) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Sun Biomedical's Interest Expense for the six months ended in Dec. 2023 was A$0.00 Mil. Its Operating Income for the six months ended in Dec. 2023 was A$-6.76 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2023 was A$0.00 Mil.

Sun Biomedical's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Sun Biomedical had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Dimerix Ltd has enough cash to cover all of its debt. Its financial situation is stable.

Sun Biomedical (ASX:SBN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sun Biomedical Ltd (ASX:SBN) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

DXB:Australia

Address

425 Smith Street, Fitzroy, VIC, AUS, 3065

Website

https://www.dimerix.com

Dimerix Ltd is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs. The company is developing five product candidates: DMX-200 for FSGS; DMX-200 for diabetic kidney disease; DMX-200 for COVID-19 pneumonia patients in ICU; DMX-200 for respiratory complications in Covid-19 patients; and DMX-700 for COPD; as well as the proprietary ReceptorHIT assay technology.

Sun Biomedical (ASX:SBN) Headlines

No Headlines